Neuphoria Therapeutics (NEUP) Exchange Rate Effect (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Exchange Rate Effect of $527059.0 for Q1 2026, up 520.3% year-over-year from $84969.0 in Q1 2025, and up 78.42% quarter-over-quarter from $295406.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Exchange Rate Effect for 4 consecutive years, with $527059.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 520.3% year-over-year to $527059.0; the TTM figure through Mar 2026 stood at $852616.0 (up 4384.86% YoY), while the FY2025 annual figure was -$3750.0, down 104.87% from the prior year.
- Exchange Rate Effect climbed to $527059.0 in Q1 2026 per NEUP's latest filing, from $295406.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $527059.0 in Q1 2026 and bottomed at -$276692.0 in Q4 2024.
- Historically, Exchange Rate Effect has averaged $79657.6 across 4 years, with a median of $72367.0 in 2024.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect tumbled 180.61% — and 2026, when it jumped 520.3%.
- Neuphoria Therapeutics' Exchange Rate Effect stood at $343242.0 in 2023, then sank by 180.61% to -$276692.0 in 2024, then jumped by 206.76% to $295406.0 in 2025, then soared by 78.42% to $527059.0 in 2026.
- Business Quant data shows NEUP's Exchange Rate Effect at $527059.0 in Q1 2026, $295406.0 in Q4 2025, and -$19455.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.13 Mn | 1.69 Mn | - | 527,059.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 527,059.00 |
| Mar 31, 2026 | 527,059.00 |
| Dec 31, 2025 | 295,406.00 |
| Dec 31, 2025 | 295,406.00 |
| Sep 30, 2025 | -19,455.00 |
| Sep 30, 2025 | -19,455.00 |
| Jun 30, 2025 | 49,606.00 |
| Jun 30, 2025 | 49,606.00 |
| Mar 31, 2025 | 84,969.00 |
| Mar 31, 2025 | 84,969.00 |
| Dec 31, 2024 | -276,692.00 |
| Dec 31, 2024 | -276,692.00 |
| Sep 30, 2024 | 138,367.00 |
| Sep 30, 2024 | 138,367.00 |
| Jun 30, 2024 | 72,367.00 |
| Jun 30, 2024 | 72,367.00 |
| Mar 31, 2024 | -185,862.00 |
| Mar 31, 2024 | -185,862.00 |
| Dec 31, 2023 | 343,242.00 |
| Dec 31, 2023 | 343,242.00 |